Introduction {#Sec1}
============

Type 2 diabetes mellitus is a multifactorial disease with a complex pathophysiology that includes defects in insulin production and a failure in peripheral tissues to take up glucose in response to insulin. Signalling via phosphatidylinositol 3-kinase (PI3K) is a key pathway in the regulation of glucose uptake by insulin \[[@CR1]\]. Activation of PI3K via insulin receptor substrate-1 causes PI3K to phosphorylate inositol-containing phospholipids at the 3′-position of the inositol ring, increasing the levels of the lipid messenger phosphatidylinositol 3,4,5-trisphosphate (PIP~3~), among others. PIP~3~ activate a phosphoinositide kinases, which in turn phosphorylate and activate protein kinase B (PKB), also known as Akt, a key effector kinase for many of the downstream metabolic effects initiated by insulin via PI3K. The phosphatase and tensin homologue (PTEN) is a phosphatase which recognises both protein and lipid substrates. As a lipid phosphatase, PTEN dephosphorylates PIP~3~ at the 3′-position of the inositol ring, thereby acting as an antagonist to PI3K signalling \[[@CR2], [@CR3]\]. *PTEN* was originally identified as a tumour suppressor gene, and is one of the most commonly mutated genes in human cancer \[[@CR4]--[@CR6]\]. Mutation or deletion of *PTEN* has been identified in many cancers including prostate, brain, breast, endometrium and skin \[[@CR4]--[@CR8]\].

As many of the metabolic outcomes of insulin are achieved through recruitment of PI3K and the subsequent rise in PIP~3~ levels, PTEN may have a critical role in modulating sensitivity to insulin-stimulated glucose uptake. Recent studies in which *Pten* was ablated specifically in liver, adipose tissue and muscle in mice by Cre recombinase-based strategies have shown a role for Pten in the regulation of insulin sensitivity in those organs, and highlighted the contributions of those organs to glucose homeostasis of the whole animal \[[@CR9]--[@CR11]\]. However, the effect of global reduction of Pten levels on glucose uptake and metabolism has not yet been shown in an in vivo mouse model. Unfortunately, experimental genetic inactivation of both *Pten* alleles (*Pten*^*−/−*^) results in early embryonic lethality \[[@CR6], [@CR12]\]. Thus mice harbouring inactivation of one *Pten* allele (haploinsufficiency, *Pten*^+/−^) are an important experimental model for studying the role of Pten in vivo. Haploinsufficiency for *Pten* has important consequences for cell proliferation and tumorigenesis in mice \[[@CR6], [@CR12]--[@CR14]\]. *Pten*^+/−^ mice exhibit defective apoptosis in T cells, B cells and macrophages and spontaneous neoplasms in various tissues including prostate, liver, endometrium and others \[[@CR12]--[@CR14]\]. Here we show that *Pten* haploinsufficiency results in insulin hypersensitivity and enhanced insulin-mediated glucose uptake.

Materials and methods {#Sec2}
=====================

**Experimental animals** All laboratory animals were cared for and used according to guidelines of the Canadian Council on Animal Care. *Pten*^+/−^ mice were generated by R. Parsons \[[@CR12]\]. These mice were backcrossed with C57BL6 mice for more than ten generations. The genotypes of the mice were determined as described \[[@CR12]\].

**Blood glucose determination** For determination of blood glucose levels, glucose levels in blood samples taken from tail vein were determined using a One Touch Ultra blood glucose monitor (LifeScan Inc., Milpitas, CA, USA). For the glucose tolerance test, mice were fasted overnight (15 h) prior to i.p. injection of glucose (2 mg/g body weight). Blood glucose levels were then determined at the indicated time-points following glucose injection. For the insulin challenge test, mice were fasted for 15 h prior to i.p. injection of 0.6 mU insulin/g body weight. Blood glucose levels were then determined at the indicated time-points following insulin injection.

**Determination of insulin in plasma** Mice were fasted for 15 h, then approximately 100 μl of blood was collected from the tail vein using pipette tips precoated with heparin. The mice were then injected i.p. with 2 mg glucose/g body weight, and a second blood sample was obtained 15 min following injection. The blood samples were centrifuged at 805 *g* in a table-top centrifuge, and insulin in the plasma fraction was determined using an insulin ELISA system (ALPCO Diagnostics, Salem, NH, USA) according to the manufacturer's instructions.

**Isolation of pancreatic islets and glucose-stimulated insulin release** Islets were isolated from pancreata of mice as described \[[@CR15]\]. Pancreata from three mice were pooled. After 24 h in culture, islets were preincubated in Krebs--Ringer bicarbonate buffer plus 0.1% BSA (KRBB-BSA) and 1.67 mmol/l glucose. The islet cells were incubated for 1 h in 1 ml KRBB-BSA containing the desired concentration of glucose (1.67 or 16.7 mmol/l). The incubation medium was then collected, and centrifuged and the supernatant fractions were used for assay of insulin content by ELISA. Total extractable insulin in islets was determined by adding 0.5 ml lysis buffer (1 mol/l acetic acid with 0.1% BSA) to the islet pellet. Cell debris was pelleted by centrifugation, and the supernatant fraction was used for insulin assay.

**Fluorescent immunohistochemistry of pancreatic islets** Immunocytochemistry has been described \[[@CR16]\]. Pancreata from wild-type and *Pten*^+/−^ mice were embedded in paraffin. Five-micron sections were incubated for 1 h at room temperature with guinea-pig anti-insulin antibody (1:100 dilution; Dako, Mississagua, ON, Canada) and rabbit anti-glucagon antibody (Dako; 1:75 dilution). Sections were visualised by incubation with Alexa--Fluor 488 goat anti-guinea-pig (Invitrogen, Molecular Probes, Burlington, ON, Canada; 1:100 dilution) and Texas Red donkey anti-rabbit antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA; 1:100 dilution). Sections were examined by fluorescence microscopy.

**Beta cell mass calculation** Following insulin immunostaining, pancreatic sections were captured under an FITC filter using a Zeiss Axioplan 2 microscope equipped for epifluorescence and Pathvysion imaging software. The insulin immunopositive area (as a proportion of pancreatic area) was determined in at least six fields per section using Zeiss AxioVision software, performed on eight pancreatic sections per mouse. Beta cell mass was calculated as pancreatic mass times the percent beta cell area for each mouse.

**2-\[^18^F\]fluoro-2-deoxyglucose uptake and microPET scanning** Mice were fasted for 15 h prior to i.p. injection with 0.6 mU insulin/g body weight. Twenty minutes after insulin injection, mice were injected with 2-\[^18^F\]fluoro-2-deoxyglucose (^18^FDG) (4.1 MBq) via the tail vein, and whole-body distribution of ^18^FDG was monitored by positron emission tomography (PET) using a microPET R4 tomograph (Concorde Microsystems, Knoxville, TN, USA). The image data were attenuation-corrected using a ^68^Ge rod source. Wild-type and *Pten*^+/−^ mice were positioned side-by-side and scanned simultaneously for 60 min after ^18^FDG injection. Data were analysed using the manufacturer's software, ASIPro VM 5.0.1.0. For data analysis, regions of interest (ROIs) were specified in the coronal section of a hindlimb for each mouse. The ^18^FDG activities in each ROI were summed across all coronal planes, and expressed as a proportion of ^18^FDG in the whole mouse (total ^18^FDG activity was also taken as the sum of activity across coronal planes).

**Primary myocyte culture** Primary myocytes were cultured from fore- and hindlimbs from wild-type and *Pten*^+/−^ mice according to a protocol adapted from Springer et al. \[[@CR17]\]. Skeletal muscle was excised and minced and then incubated at 37°C for 2 h with 2.4 units/ml dispase II. Dispase digestion was halted by addition of 10 ml F-10-based myocyte medium (400 ml F-10 nutrient mixture, 100 ml fetal bovine serum, 25 μg basic fibroblast growth factor, penicillin/streptomycin). The tissue slurry was then strained through a fine metal mesh and centrifuged at 500 *g* for 5 min. The supernatant fraction was removed to a fresh centrifuge tube and the pellet was resuspended and plated to a 5-cm collagen-coated culture dish in a total of 4 ml F-10-based medium. The supernatant fraction was re-centrifuged and the pellet was pooled with the first. The cells were passaged when they reached 70--80% confluence. To enrich for myocytes, the old medium was removed by aspiration, the cells washed with PBS, then incubated in a film of this buffer for 15 min. Myocytes were loosened from the dish by striking the dish several times sharply on the bench top. Cells were washed from the dish with PBS. The PBS incubation was repeated and the cells were pooled. Cells kept in culture for more than 5--6 days began to exhibit the elongated morphology typical of myotubes \[[@CR18]\]. Cells in these older cultures also exhibited spontaneous twitching. All experiments were performed with cells on days 2--3 of culture.

**2-Deoxy\[^3^H\]glucose uptake** Experiments were performed on wild-type or *Pten*^+/−^ cells from passage two to eight, grown on 24-well (1-cm diameter wells) plates. Cells were preincubated in serum-free medium for 12 h prior to experiments. The cells were washed twice with HEPES-buffered saline (140 mmol/l NaCl, 20 mmol/l HEPES, 2.5 mmol/l MgSO~4~, 1 mmol/l CaCl~2~, 5 mmol/l KCl, pH 7.4), then incubated with 10 μmol/l 2-deoxy\[^3^H\]glucose (0.037 MBq/ml) for 5, 10, 20 or 30 min, in the absence or presence of 0.1 μmol/l insulin. At the end of the incubation period, the radioactive substrate was removed, and the cells were washed three times with ice-cold 20 mmol/l glucose. Cells were lysed with 0.2 ml 2% SDS, and the lysates were used for scintillation counting. Non-specific diffusion of 2-deoxy\[^3^H\]glucose was determined by incubating cells in the presence of 2-deoxy\[^3^H\]glucose and 10 μmol/l cytochalasin B, a specific inhibitor of glucose uptake \[[@CR19]\].

**Determination of cell-surface GLUT1 and GLUT4 levels** Primary myocytes were grown in 10-cm culture dishes. The cells were rinsed with PBS, and incubated with 0.5 mg/ml sulpho-NHS-LC-biotin (Pierce Biotechnology, Rockford, IL, USA) in PBS for 20 min. Cells are impermeable to this reagent and it labels the amine groups of cell-surface proteins. Following the incubation, the cells were washed three times with PBS, then lysed with 0.5 ml lysis buffer (1% NP-40, 150 mmol/l NaCl, 50 mmol/l Tris pH 7.5, including protease and phosphatase inhibitors). Protein was quantified with a BCA protein assay kit (Pierce). Streptavidin-agarose beads (Pierce) were pre-blocked by incubation with 2% BSA in lysis buffer. Each sample (1.2 mg protein) was incubated with the streptavidin beads (100 μl, 50% bead slurry) for 1 h at room temperature. The beads were washed five times, for 30--60 min each wash, using lysis buffer containing 0.1% SDS. After the final wash, 50 μl SDS sample-loading buffer were added, and heated at 95°C for 10 min, then vortexed to elute the biotinylated proteins. The proteins in the supernatant fractions were analysed by SDS-PAGE, then transferred to nitrocellulose. Proteins were probed using polyclonal antibodies against GLUT1 and GLUT4 (also known as SCLA2A1 and SCLA2A4, respectively).

**Western immunoblotting for PKB, phospho-PKB and phospho-glycogen synthase kinase 3 (GSK3)-α/β** Total protein extracts of primary myocytes were prepared by lysing cells in NP-40-based lysis buffer. Thirty to fifty micrograms of protein per sample were analysed by SDS-PAGE, then transferred to nitrocellulose. Rabbit polyclonal anti-PKB, anti-phospho-PKB (Ser473) and anti-phospho-GSK3-α/β (Ser21/9) antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Mouse monoclonal anti-vinculin antibody was obtained from Sigma (St Louis, MO, USA). Horseradish peroxidase-conjugated secondary antibodies were obtained from Dako. Protein bands were visualised using an enhanced chemiluminescence system and autoradiography by exposure to X-ray film.

**Statistical analysis** Statistical analysis was performed using Student's *t* test. Significance was assessed at the 95% confidence level.

Results {#Sec3}
=======

As glucose metabolism may be altered due to a change in insulin sensitivity in *Pten*^+/−^ mice, blood glucose levels in wild-type and *Pten*^+/−^ mice were determined. Slight but statistically significant hypoglycaemia was observed in *Pten*^+/−^ mice during ad libitum feeding (11.3% lower blood glucose in *Pten*^+/−^ mice) (Table [1](#Tab1){ref-type="table"}). Fasting caused a drop in glucose levels in both groups, with slight but significant hypoglycaemia in the *Pten*^+/−^ group (10.8% lower blood glucose) relative to wild-type mice. An insulin challenge test revealed hypersensitivity to insulin in *Pten*^+/−^ mice (Fig. [1](#Fig1){ref-type="fig"}a). Following i.p. insulin injection (0.6 mU/g body weight), blood glucose levels in *Pten*^+/−^ mice remained depressed at all time-points measured (up to 120 min). In contrast, wild-type mice started to recover after 30 min, and glucose levels returned to fasting levels 120 min after injection. A glucose tolerance test showed that *Pten*^+/−^ mice had greater glucose tolerance than wild-type mice (Fig. [1](#Fig1){ref-type="fig"}b). After i.p. glucose injection, blood glucose levels in *Pten*^+/−^ mice returned to fasting levels in less than 60 min, approximately twice as rapidly as in wild-type mice. Table 1Blood glucose levels in wild-type and *Pten*^+/−^ mice during ad libitum feeding and after a 15-h fast Mean blood glucose±SD (mmol/l)*p* value (independent Student's *t* test)Wild-typePten^+/−^Ad libitum feeding7.1 ± 0.4 (*n* = 5)6.3 ± 0.2 (*n* = 4)0.006Fasting6.5 ± 0.3 (*n* = 5)5.8 ± 0.3 (*n* = 5)0.008Fig. 1Insulin hypersensitivity in *Pten*^+/−^mice. **a** Insulin challenge test. Mice were fasted for 15 h prior to i.p. injection of insulin (0.6 mU/g body weight). Blood glucose levels were determined at the indicated times. Means±SEM for six wild-type mice (*white circles*) and six *Pten*^+/−^ mice (*black circles*). **b** Glucose tolerance test. Mice were fasted for 15 h prior to i.p. injection of glucose at 2 mg/g body weight. Means±SEM for six wild-type mice (*white circles*) and seven *Pten*^+/−^ mice (*black circles*)

The observed difference in ability to normalise blood glucose levels could be due to differences in insulin sensitivity or islet function and insulin production. We therefore investigated insulin levels in the mice, as well as properties of pancreatic cell morphology and function. Fasting plasma insulin levels were slightly but significantly lower in *Pten*^+/−^ mice (Table [2](#Tab2){ref-type="table"}), which is consistent with increased peripheral insulin sensitivity. Fifteen minutes after i.p. glucose administration (2 mg glucose/g body weight), similar increases in plasma insulin were observed in the two groups (Table [2](#Tab2){ref-type="table"}), suggesting that there is no marked difference in insulin production in the *Pten*^+/−^ mice. Insulin released from islets isolated from *Pten*^+/+^ and *Pten*^+/−^ mice was also examined. Islets were cultured as described in [Materials and methods](#Sec2){ref-type="sec"}, and incubated in the presence of low (1.67 mmol/l) or high (16.7 mmol/l) glucose. Insulin released into the medium was determined by ELISA and calculated as percentage of total insulin content in the islets. Per cent of total insulin release (presented as mean value±SD) was similar under conditions of low glucose (*Pten*^+/+^, 3.3 ± 0.4% vs *Pten*^+/−^, 2.8 ± 0.3%; *p* \> 0.05 no significant difference, *n* = 3 per group) and high glucose (*Pten*^+/+^, 4.2 ± 0.7% vs *Pten*^+/−^, 3.7 ± 0.2%; *p* \> 0.05 no significant difference, *n* = 3 per group). Table 2Plasma insulin levels in wild-type and *Pten*^+/−^ mice after fasting, and 15 min after i.p. glucose administration (2 mg glucose/g body weight) Mean plasma insulin±SD (ng/ml)*p* value (independent Student's *t* test)Wild-type (*n* = 7)Pten^+/−^ (*n* = 6)Fasting0.50 ± 0.040.36 ± 0.100.05Post-glucose challenge1.8 ± 0.52.4 ± 0.4\>0.05 (not significant)

Immunofluorescence of pancreatic sections revealed similar morphology of islets of wild-type and *Pten*^+/−^ mice (Fig. [2](#Fig2){ref-type="fig"}), suggesting *Pten* haploinsufficiency has no marked effect on islet morphology. Accordingly, beta cell mass was not found to be significantly different between wild-type and *Pten*^+/−^ mice (Table [3](#Tab3){ref-type="table"}). Fig. 2Pancreatic islet morphology and immunohistochemistry for insulin (*green*) and glucagon (*red*) in wild-type (**a**) and *Pten*^+/−^ (**b**) mice. Pancreatic sections were immunostained as described in [Materials and methods](#Sec2){ref-type="sec"} and visualised by fluorescence microscopy. Original magnification ×40Table 3Pancreatic beta cell mass of *Pten*^+/+^ and *Pten*^+/−^ littermates Mean beta cell mass±SE (mg)*Pten*^+/+^1.24 ± 0.30 (*n* = 3)*Pten*^+/−^1.29 ± 0.15 (*n* = 3)

Skeletal muscle is an important tissue involved in insulin-stimulated glucose uptake \[[@CR10], [@CR20]\]. In vivo glucose uptake was assessed by monitoring distribution of ^18^FDG into muscles in real-time by PET. ^18^FDG is transported into cells by glucose transporters and is phosphorylated by hexokinase, but is not a substrate for further metabolism in the glycolytic pathway \[[@CR21]\]. To compare insulin-stimulated glucose uptake in wild-type and *Pten*^+/−^ mice, the mice were fasted for 15 h, then injected i.p. with insulin (0.6 mU/g body weight) 20 min prior to injection with ^18^FDG via the tail vein. Mice were imaged for ^18^FDG uptake into the hindlimb for 60 min (Fig. [3](#Fig3){ref-type="fig"}a). ^18^FDG activity in hindlimbs was analysed as a proportion of total body activity, and was found to be higher in *Pten*^+/−^ than in wild-type mice at all time-points (Fig. [3](#Fig3){ref-type="fig"}b). Fig. 3Insulin-stimulated uptake of ^18^FDG in wild-type and *Pten*^+/−^ mice. Mice were fasted for 15 h prior to i.p. injection of 0.6 mU insulin/g body weight. Twenty minutes after insulin injection, mice were injected with ^18^FDG via a tail vein, and whole-body distribution of ^18^FDG was monitored by microPET for 60 min. The experiment was repeated three times with similar results. Typical results are shown. **a--f** Imaging of ^18^FDG distribution in coronal section; wild-type mouse is on the left and *Pten*^+/−^ mouse is on the right (**a** 5 min; **b** 15 min; **c** 25 min; **d** 35 min; **e** 45 min; **f** 55 min). Hindlimb muscles were highlighted as regions of interest, and ^18^FDG activity in each region of interest quantified across coronal planes at each time-point, as described in [Materials and methods](#Sec2){ref-type="sec"}. **g** Graphical representation of relative ^18^FDG activity. Data are shown as proportion of ^18^FDG activity in hindlimbs relative to activity in whole body for wild-type mice (*circles*) and *Pten*^+/−^ mice (*triangles*) (mean±SD; *n* = 3 per point)

Tissues from *Pten*^+/−^ mice exhibited slightly reduced levels of Pten protein relative to wild-type mice \[[@CR14], [@CR22]--[@CR24]\]. In order to examine cellular glucose uptake and intracellular signalling events, primary myocytes were cultured from hindlimb muscle of wild-type and *Pten*^+/−^ mice. In the absence of insulin, cells from *Pten*^+/−^ mice showed increased 2-deoxy\[^3^H\]glucose uptake at all time-points measured, to a maximum increase of twofold relative to wild-type cells at the 3 h time-point (Fig. [4](#Fig4){ref-type="fig"}a). This result, together with the lower fasting glucose level of *Pten*^+/−^ mice, suggest that the PI3K/PKB pathway was chronically activated in *Pten*^+/−^ animals. In the presence of insulin, *Pten*^+/−^ cells exhibited a further increase in glucose uptake, up to threefold greater than wild-type cells. This observation is consistent with the above results of the insulin and glucose challenge tests and ^18^FDG uptake experiment in showing a hypersensitivity to insulin due to *Pten* haploinsufficiency. Fig. 4**a** 2-Deoxy\[^3^H\]glucose uptake in wild-type and *Pten*^+/−^ myocytes. Myocytes were serum-starved for 12 h prior to incubation with 10 μmol/l 2-deoxy\[^3^H\]glucose (0.037 MBq/μmol/l) for the indicated times with 0 or 1 μmol/l insulin. Following incubation cells were lysed and aliquots of lysates were taken for determination of radioactivity by scintillation counting. Means±SD for three separate determinations. *White circles*, wild-type cells 0 μmol/l insulin; *black circles*, wild-type cells 1 μmol/l insulin; *white triangles*, *Pten*^+/−^ cells 0 μmol/l insulin; *black triangles*, *Pten*^+/−^ cells 1 μmol/l insulin. **b** Cell-surface GLUT1 and GLUT4 levels. Levels of cell-surface GLUT1 and GLUT4 proteins in wild-type (*WT*) and *Pten*^+/−^ cells were determined as described in [Materials and methods](#Sec2){ref-type="sec"}

Glucose transport into skeletal muscle occurs by a facilitated diffusion process mediated primarily by the glucose transporter proteins, GLUT1 and GLUT4. The level of GLUT4 at the plasma membrane is tightly regulated by insulin, whereas GLUT1 is found constitutively on the cell surface \[[@CR25]\]. Since 2-deoxy\[^3^H\]glucose uptake was elevated in *Pten*^+/−^ cells even in the absence of insulin (Fig. [4](#Fig4){ref-type="fig"}a), we analysed cell-surface GLUT4 and GLUT1 by western immunoblot as described in Materials and methods (Fig. [4](#Fig4){ref-type="fig"}b). This analysis showed increased GLUT4 at the cell surface in *Pten*^+/−^ cells, while similar GLUT1 levels were observed in the two cell types.

As PKB is a key effector kinase that mediates many of the downstream cellular events induced by the PI3K signalling pathway, including insulin-stimulated glucose uptake \[[@CR26], [@CR27]\], we determined the phosphorylation status of PKB in wild-type and *Pten*^+/−^ myocytes. Little to no phosphorylation was observed in the absence of insulin, and phosphorylation at Ser473 was observed upon addition of insulin (Fig. [5](#Fig5){ref-type="fig"}). Whereas PKB phosphorylation started to decrease after 4 h in wild-type cells in the presence of insulin, phosphorylation was sustained in *Pten*^+/−^ cells during the course of the experiment (up to 6 h). Immunoblotting for total PKB protein showed that PKB levels were consistent in *Pten*^+/−^ and *Pten*^+/+^ cells (Fig. [5](#Fig5){ref-type="fig"}). Immunoblotting for vinculin was included as a protein-loading control. An immediate downstream substrate of PKB is GSK3β. This enzyme becomes inactivated upon phosphorylation by PKB, in turn allowing its substrate, glycogen synthase, to mediate glycogen synthesis and thus promote glucose storage. Consistent with the observed enhancement of PKB phosphorylation in *Pten*^+/−^ cells, these cells also exhibited a higher degree of GSK3β phosphorylation in comparison with *Pten*^+/+^ cells (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Phosphorylation of PKB and GSK3β. Myocytes were serum-starved for 12 h prior to incubation with 1 μmol/l insulin for the indicated times. Cell lysates were prepared, and proteins were separated by PAGE followed by western immunoblot analysis for vinculin, total PKB, phospho-PKB (p-PKB S473) and phospho-GSK3β (p-GSK3β) as indicated. This experiment was repeated three times with typical results shown. *WT*, wild-type

Discussion {#Sec4}
==========

Recent studies utilising tissue-specific deletion of *Pten* in liver, adipose and muscle have shown that these organs make important contributions to the glucose homeostasis of the animal and clearly establish Pten as a negative regulator of insulin signalling in vivo \[[@CR9]--[@CR11]\]. In a separate report, in vivo antisense treatment resulted in 90% reduction of Pten levels in the liver of diabetic mice, normalising blood glucose levels and improving performance in an insulin tolerance test \[[@CR28]\]. While the above studies focused on the role of Pten in specific tissues, the current work defines the effects of partial systemic reduction of Pten on the regulation of insulin sensitivity in the context of the whole animal.

PTEN expression/activity is tightly regulated by a complex mechanism that is currently poorly understood. PTEN is transcriptionally regulated by transcription factors such as p53, Egr-1, NFκB and SMADs, while protein levels and activity are modulated by phosphorylation, oxidation, subcellular localisation, phospholipid binding and protein stability \[[@CR29]\]. Previous studies showed that *Pten* haploinsufficiency results in only a 15--50% reduction in Pten protein, leaving a substantial amount of Pten protein remaining in the tissues examined \[[@CR14], [@CR22]--[@CR24], [@CR30]\]. In our hands, western blot analysis indicated similar decreases in tissue Pten levels (data not shown). The present study provides the first evidence that *Pten* haploinsufficiency leads to insulin hypersensitivity in vivo, suggesting that even small changes in Pten levels or activity can lead to dramatic effects on insulin responses. Thus partial systemic inhibition of PTEN activity may represent a novel strategy to ameliorate the pathology of type 2 diabetes.

The PI3K/PKB signalling axis is central to maintenance of normal glucose homeostasis \[[@CR1]\]. Pten-deficient cells typically have elevated levels of intracellular PIP~3~ \[[@CR31], [@CR32]\]. The sustained phosphorylation of PKB/Akt and a downstream effector, GSK3β, observed in the current study is consistent with previous reports of elevated PKB/Akt activation as a result of impaired desensitisation of PI3K-dependent signals under conditions of Pten inactivation or inhibition \[[@CR9]--[@CR11], [@CR28]\]. A subtle reduction of Pten in the *Pten*^+/−^ mice appears sufficient to achieve a prolonged and robust insulin signal. The roles of PIP~3~ and PKB/Akt in insulin-mediated glucose uptake have been well-established; therefore, our data collectively suggest that sustained PI3K/PKB/Akt/GSK3 signalling may, in part, contribute to insulin hypersensitivity in Pten^+/−^ mice. However, other PKB/Akt-independent signalling pathways, as well as additional signals delivered by the protein phosphatase and/or adaptor functions of Pten may also contribute to the insulin hypersensitivity phenotype manifested by *Pten* haploinsufficiency.

GLUT1 glucose transporters are constitutively present at the cell surface, while GLUT4 cycles between intracellular vesicles and the cell surface in a manner controlled by insulin-mediated signalling mechanisms \[[@CR25]\]. In unstimulated fat and muscle cells, the majority of GLUT4 exists in intracellular compartments, while the insulin signal stimulates the exocytosis of GLUT4 to the cell surface. Studies involving PKB/Akt-null animals and silencing of PKB/Akt by RNA interference have demonstrated that PKB/Akt is of primary importance in GLUT4 translocation \[[@CR33]--[@CR36]\]. In the current study, we observed an enhancement of 2-deoxyglucose uptake in *Pten*^+/−^ cells even in the absence of insulin stimulation, which was consistent with our observation of increased biotinylation of GLUT4 at the cell surface, while GLUT1 levels were unaffected. However, we detected no increase in phosphorylation of PKB/Akt in the absence of insulin in *Pten*^+/−^ cells. Consistent with these observations, a recent study in which Pten was specifically knocked down by RNA interference reported slight but significant enhancement of deoxyglucose uptake in adipocytes, but no apparent increase in phosphorylation of PKB/Akt \[[@CR37]\]. These results could reflect a mechanism(s) affecting glucose transport involving Pten/PIP~3~ but independent of PKB/Akt. Such a mechanism could involve the atypical protein kinases C-λ and -ζ (PKC-λ and PKC-ζ), which, like PKB/Akt, are subject to control by PI3K via PIP~3~ and 3-phosphoinositide-dependent protein kinase-1 (PDK-1) \[[@CR38]--[@CR40]\]. A number of studies have implicated PKC-λ/ζ in insulin-stimulated glucose transport and GLUT4 translocation \[[@CR38], [@CR41]--[@CR43]\]. These studies indicate a role for PKC-λ/ζ which appears to be complementary or parallel to that of PKB/Akt.

The importance of the PI3K pathway in insulin signalling has raised interest in developing pharmaceutical antagonists targeting PIP~3~ phosphatases such as PTEN or Sh2-containing inositol 5′-phosphatase 2 (SHIP2; also known as Inppl1) in an effort to enhance insulin responsiveness in type 2 diabetes \[[@CR44]\]. While a study on *Ship2*-null mice initially implicated Ship2 as a key regulator of glucose uptake \[[@CR45]\], it was subsequently recognised that these mice also had deleted a neighbouring gene, *Phox2a*, which may have contributed to the observed phenotype (corrigendum appears in *Nature* vol. 431, p. 878). A new gene-targeted mouse has since been generated in which only the gene encoding Ship2 is deleted \[[@CR46]\]. Interestingly, this mouse does not exhibit insulin hypersensitivity but is protected against diet-induced obesity, \[[@CR46], [@CR47]\]. In the light of these new findings, our observations of dramatic enhancement of insulin sensitivity and glucose uptake resulting from *Pten* haploinsufficiency suggests that PTEN plays a role in the desensitisation of insulin signalling, and strengthens the hypothesis that PTEN is a key regulator of insulin-stimulated glucose uptake.

Type 2 diabetes is associated with insulin deficiency and resistance to insulin signalling \[[@CR48], [@CR49]\]. The current study provides further support for PTEN as a candidate for drug intervention in treating type 2 diabetes. However, enthusiasm for systemic PTEN inhibitors as a therapeutic approach for treating type 2 diabetes is tempered by the potential side-effects of such agents. Most notably, a modest reduction of Pten in *Pten*^+/−^ mice promotes tumour formation in a wide variety of tissue, suggesting that long-term chronic administration of systemic PTEN inhibitors may lead to enhanced cancer development and progression. Furthermore, the PI3K pathway is an important regulator of numerous normal cellular processes and systemic PTEN inhibition may cause dysfunction of many cells and tissues, leading to alterations in liver, kidney, brain function, etc. For example, hepatocyte-specific *Pten*-deficient mice exhibit hepatomegaly and liver steatosis \[[@CR9]\]. Systemic inhibition of PTEN may therefore be unacceptable clinically because of these inherent potential toxicities \[[@CR44]\]. However, targeted delivery of PTEN antagonists to muscle cells or adipocytes may overcome these limitations and they hold promise as clinically viable agents in treatment of type 2 diabetes \[[@CR44]\]. This study shows that partial inhibition of Pten is sufficient to enhance insulin sensitivity. This observation is important from a therapeutic standpoint, as most drugs are unlikely to completely inhibit enzyme activity in vivo, nor would complete inhibition be desirable given the potential for cancer development resulting from chronic or overactivation of the PI3K/PKB pathway \[[@CR12], [@CR14], [@CR23]\].

In conclusion, *Pten* haploinsufficiency results in insulin hypersensitivity, which underscores the importance of PTEN in attenuating insulin signals, and suggests that small-molecule drugs that antagonise PTEN activity may represent a novel class of insulin-sensitising agents and targeted delivery of these agents to muscle cells or adipocytes may have potential clinical utility in treating insulin resistance observed in type 2 diabetes.
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